Cargando…
Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
Pancreatic cancer represents one of the most lethal cancer types worldwide, with a 5-year survival rate of less than 5%. Due to the inability to diagnose it promptly and the lack of efficacy of existing treatments, research and development of innovative therapies and new diagnostics are crucial to i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536303/ https://www.ncbi.nlm.nih.gov/pubmed/37765331 http://dx.doi.org/10.3390/pharmaceutics15092363 |
_version_ | 1785112833906704384 |
---|---|
author | Viegas, Cláudia Patrício, Ana B. Prata, João Fonseca, Leonor Macedo, Ana S. Duarte, Sofia O. D. Fonte, Pedro |
author_facet | Viegas, Cláudia Patrício, Ana B. Prata, João Fonseca, Leonor Macedo, Ana S. Duarte, Sofia O. D. Fonte, Pedro |
author_sort | Viegas, Cláudia |
collection | PubMed |
description | Pancreatic cancer represents one of the most lethal cancer types worldwide, with a 5-year survival rate of less than 5%. Due to the inability to diagnose it promptly and the lack of efficacy of existing treatments, research and development of innovative therapies and new diagnostics are crucial to increase the survival rate and decrease mortality. Nanomedicine has been gaining importance as an innovative approach for drug delivery and diagnosis, opening new horizons through the implementation of smart nanocarrier systems, which can deliver drugs to the specific tissue or organ at an optimal concentration, enhancing treatment efficacy and reducing systemic toxicity. Varied materials such as lipids, polymers, and inorganic materials have been used to obtain nanoparticles and develop innovative drug delivery systems for pancreatic cancer treatment. In this review, it is discussed the main scientific advances in pancreatic cancer treatment by nano-based drug delivery systems. The advantages and disadvantages of such delivery systems in pancreatic cancer treatment are also addressed. More importantly, the different types of nanocarriers and therapeutic strategies developed so far are scrutinized. |
format | Online Article Text |
id | pubmed-10536303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105363032023-09-29 Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems Viegas, Cláudia Patrício, Ana B. Prata, João Fonseca, Leonor Macedo, Ana S. Duarte, Sofia O. D. Fonte, Pedro Pharmaceutics Review Pancreatic cancer represents one of the most lethal cancer types worldwide, with a 5-year survival rate of less than 5%. Due to the inability to diagnose it promptly and the lack of efficacy of existing treatments, research and development of innovative therapies and new diagnostics are crucial to increase the survival rate and decrease mortality. Nanomedicine has been gaining importance as an innovative approach for drug delivery and diagnosis, opening new horizons through the implementation of smart nanocarrier systems, which can deliver drugs to the specific tissue or organ at an optimal concentration, enhancing treatment efficacy and reducing systemic toxicity. Varied materials such as lipids, polymers, and inorganic materials have been used to obtain nanoparticles and develop innovative drug delivery systems for pancreatic cancer treatment. In this review, it is discussed the main scientific advances in pancreatic cancer treatment by nano-based drug delivery systems. The advantages and disadvantages of such delivery systems in pancreatic cancer treatment are also addressed. More importantly, the different types of nanocarriers and therapeutic strategies developed so far are scrutinized. MDPI 2023-09-21 /pmc/articles/PMC10536303/ /pubmed/37765331 http://dx.doi.org/10.3390/pharmaceutics15092363 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Viegas, Cláudia Patrício, Ana B. Prata, João Fonseca, Leonor Macedo, Ana S. Duarte, Sofia O. D. Fonte, Pedro Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems |
title | Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems |
title_full | Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems |
title_fullStr | Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems |
title_full_unstemmed | Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems |
title_short | Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems |
title_sort | advances in pancreatic cancer treatment by nano-based drug delivery systems |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536303/ https://www.ncbi.nlm.nih.gov/pubmed/37765331 http://dx.doi.org/10.3390/pharmaceutics15092363 |
work_keys_str_mv | AT viegasclaudia advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems AT patricioanab advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems AT pratajoao advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems AT fonsecaleonor advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems AT macedoanas advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems AT duartesofiaod advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems AT fontepedro advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems |